Momenta Pharmaceuticals Competitors and Similar CompaniesClear all
Momenta Pharmaceuticals's competitors and similar companies include Alnylam, Sorrento Therapeutics, scPharmaceuticals and ANI Pharmaceuticals.
 Momenta Pharmaceuticals Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the characterization and process engineering of complex molecules. |  Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. |  Sorrento Therapeutics Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
|  scPharmaceuticals scPharmaceuticals, a biopharmaceutical company, develops a portfolio of transformative pharmaceutical products for subcutaneous delivery. |  ANI Pharmaceuticals ANI Pharmaceuticals develops, manufactures and markets top quality prescription pharmaceuticals, made in the U.S.A. | |
Founding Date | Founding Date 2001 | Founding Date 2002 | Founding Date 2006 | Founding Date 2014 | Founding Date 1996 |
Type | Type Subsidiary | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Cambridge, US HQ Dublin, IE Cambridge, US | Locations San Diego, US HQ San Diego, US | Locations Burlington, US HQ | Locations Baudette, US HQ Oakville, CA Baudette, US | |
Employees | Employees 76 | Employees 1,32324% increase | Employees 31019% decrease | Employees 96256% increase | Employees 33813% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 36.5 b | Valuation ($) 1.5 m | Valuation ($) 221.6 m | Valuation ($) 1.2 b |
Financial | |||||
Revenue (est.) | Revenue (est.) $23.9m (FY, 2019) | Revenue (est.) $3.7b (FY, 2025) | Revenue (est.) $62.8m (FY, 2022) | Revenue (est.) $36.3m (FY, 2024) | Revenue (est.) $883.4m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $677.2m (FY, 2025) | Cost of goods N/A | Cost of goods $11.4m (FY, 2024) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit $3b (FY, 2025) | Gross profit N/A | Gross profit $25m (FY, 2024) | Gross profit N/A |
Net income | Net income ($290.1m) (FY, 2019) | Net income $313.7m (FY, 2025) | Net income ($577.8m) (FY, 2022) | Net income ($85.1m) (FY, 2024) | Net income N/A |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 1.5b | Total funding raised $ 42.6m | Total funding raised $ 62.5m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Alnylam
HQ
Cambridge, US
Employees
1,323↑ 24% increase
Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
View companySorrento Therapeutics
HQ
San Diego, US
Employees
310↓ 19% decrease
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
View companyscPharmaceuticals
HQ
Burlington, US
Employees
96
scPharmaceuticals, a biopharmaceutical company, develops a portfolio of transformative pharmaceutical products for subcutaneous delivery.
View companyANI Pharmaceuticals
HQ
Baudette, US
Employees
338↑ 13% increase
ANI Pharmaceuticals develops, manufactures and markets top quality prescription pharmaceuticals, made in the U.S.A.
View company